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*Corresponding Author. E-mail: jtschaff@iu.edu, Twitter: @jtschaff.Volume 6Study objective: We seek to test the efﬁcacy of noninvasive sphenopalatine ganglion block for the treatment of acute
anterior headache in the emergency department (ED) using a novel noninvasive delivery device.
Methods: We conducted a randomized, double-blind, placebo-controlled trial evaluating bupivacaine anesthesia of the
sphenopalatine ganglion for acute anterior or global-based headache. This study was completed in 2 large academic
EDs. Bupivacaine or normal saline solution was delivered intranasally (0.3 mL per side) with the Tx360 device. Pain and
nausea were measured at 0, 5, and 15 minutes by a 100-mm visual analog scale. The primary endpoint was a 50%
reduction in pain at 15 minutes. Telephone follow-up assessed 24-hour pain and nausea through a 0- to 10-point verbal
scale and adverse effects.
Results: The median reported baseline pain in the bupivacaine group was 80 mm (IQR 66 mm - 93 mm) and 78.5 mm
(IQR 64 mm to 91.75 mm) in the normal saline solution group. A 50% reduction in pain was achieved in 48.8% of the
bupivacaine group (20/41 patients) versus 41.3% in the normal saline solution group (19/46 patients), for an absolute
risk difference of 7.5% (95% conﬁdence interval [CI] –13% to 27.1%). As a secondary outcome, at 24 hours, more
patients in the bupivacaine group were headache free (24.7% difference; 95% CI 2.6% to 43.6%) and more were
nausea free (16.9% difference; 95% CI 0.8% to 32.5%).
Conclusion: For patients with acute anterior headache, sphenopalatine ganglion block with the Tx360 device with
bupivacaine did not result in a signiﬁcant increase in the proportion of patients achieving a greater than or equal to 50%
reduction in headache severity at 15 minutes compared with saline solution applied in the same manner. [Ann Emerg
Med. 2015;65:503-510.]
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Background
Acute headache is a frequent chief complaint in patients
presenting to the emergency department (ED), accounting
for 1% to 2% of all ED visits.1,2 The primary goals for
the management of headache in the ED are to differentiate
the life-threatening causes of headache from benign
headache and to relieve headache pain. Although there
are effective medications available to relieve headache,
oral therapies often fail or are only partially effective,
and emergency physicians often resort to intravenous
therapies.3 Common treatments (eg, prochlorperazine,
droperidol, metoclopramide) are most effective only when
used intravenously and have adverse effects, and some have5, no. 5 : May 2015recently been subject to supply shortages.3-7 An ideal headache
treatment is one that would be fast acting and effective,
avoid the need for intravenous access, and have minimal
adverse effects.
The sphenopalatine ganglion plays a pivotal role in
nociception of headache and facial pain.8-12 Sphenopalatine
ganglion block has been described for treatment of facial
and head pain, including cluster headaches, trigeminal
neuralgia, and postoperative pain relief for ear, nose, and
throat surgeries.13-17 Recent evidence has implicated the
sphenopalatine ganglion as an important neural relay point
for common migraine.8-12 Activation of the sphenopalatine
ganglion causes parasympathetic-mediated vasodilation of
the cerebral vasculature, producing cephalgia. AnesthetizingAnnals of Emergency Medicine 503
Figure 1. Sphenopalatine ganglion block with the Tx360
device. The device is positioned in the nares as shown, aimed
slightly medial and inferior. The attached syringe is advanced
into the device, advancing the catheter into the open space
in the nasopharynx to the correct location. The medication is
then delivered directionally laterally and superiorly to the
sphenopalatine ganglion.
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What is already known on this topic
Acute emergency department (ED) headache
treatment leaves many with residual symptoms or
adverse effects. Sphenopalatine ganglion block is one
tool used in select patients.
What question this study addressed
Does a proprietary local anesthetic sphenopalatine
ganglion block delivery system allow successful acute
ED treatment of anterior or global headache patients?
What this study adds to our knowledge
In a prospective, randomized, placebo-controlled trial
of 93 patients, the delivery of bupivacaine did not
improve short-term outcomes.
How this is relevant to clinical practice
This study provides no support for using noninvasive
sphenopalatine block for acute symptom relief.the ganglion is thought to attenuate this dilation, resulting
in rapid relief of symptoms.11
Importance
Conventional techniques for delivering anesthetic to the
sphenopalatine ganglion include stereotactic, endoscopic, or
ﬂuoroscopic approaches. Direct access to the ganglion is
blocked by its location deep in the nasopharynx in a recess
posterior to the middle turbinate. This makes transnasal
approaches difﬁcult and unreachable by a simple cotton-tip
applicator. Other transnasal approaches are imperfect and
classically combinedwith recumbent position, larger volumes
and time, or ﬂuoroscopy.18,19 The difﬁculty, discomfort, or
time involved in conventional techniques for anesthetizing
the sphenopalatine ganglion are not practical for an ED
setting and may be preventing study of this treatment.
A recently Food and Drug Administration–cleared
device (Tx360; Tian Medical LLC, Lombard, IL) may
facilitate the procedure of anesthetizing this ganglion. This
device is designed to position a ﬂexible microcatheter,
inserted through the nares, in close proximity to the ganglia
in the posterior nasopharynx (Figure 1). At the tip of this
catheter, a small delivery port is engineered to directionally
spray the medication superiorly, laterally, and anteriorly to
the sphenopalatine ganglion. The procedure takes as little
as 10 seconds per side to perform in awake patients
who remain seated during the procedure.19 If effective for
acute headache, sphenopalatine ganglion block using this504 Annals of Emergency Medicinetechnique could be a feasible alternative to conventional
therapies in the ED.Goals of This Investigation
The objective of this study was to evaluate the efﬁcacy of
sphenopalatine ganglion block with the Tx360 device for
the treatment of acute frontal headache in patients
presenting to the ED. Our hypothesis was that bupivacaine
delivered to the sphenopalatine ganglion would achieve a
50% reduction in acute anterior headache pain in a greater
proportion of patients than normal saline solution placebo
delivered in the same manner.MATERIALS AND METHODS
Study Design and Setting
We conducted a randomized, double-blind, placebo-
controlled trial in 2 urban EDs. Both EDs are academic
Level I trauma centers with an annual census of 100,000 to
110,000 patients per year. We enrolled eligible patients in a
convenience sample from October 1, 2012, to December
1, 2013, according to research assistant coverage. The study
was approved by the institutional review board of Indiana
University School of Medicine. This study is reported in
accordance with Consolidated Standards of Reporting
Trials (CONSORT) guidelines.Selection of Participants
Patients aged 18 to 65 years were eligible if they
presented to the ED with a frontal-based crescendo-onset
headache and a normal neurologic examination result.Volume 65, no. 5 : May 2015
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temporal, orbital, maxillary, or mandibular region. Speciﬁc
classiﬁcation of the type of headache was not attempted or
required for enrollment. Patients gave consent for
participation to a research assistant, and formal written
informed consent was obtained.
Patients with headaches that originate in the posterior or
occipital region were excluded because anesthesia of the
sphenopalatine ganglion is less likely to affect these
headaches, according to the theorized mechanism of action.
Patients were also excluded if they had a temperature greater
than 37.7C (100F), had signs of acute or chronic sinusitis,
exhibited nuchal rigidity, or had sudden-onset headache.
Other exclusion criteria included self-medication for
headache with pain or antinausea medication within 4 hours
preceding enrollment; bleeding diatheses; pregnancy;
peripheral vascular disease; cancer; HIV; history of nasal
insufﬂation of illicit drugs; nasal septal deformity; recent
nasal or sinus surgery; nasal passage dryness, soreness,
oozing, or bleeding; allergy to local anesthetics; participation
in another investigational trial within the preceding 30 days;
or lack of telephone for follow-up contact.
Interventions
Patients who qualiﬁed for the study were randomly
assigned in a 1:1 ratio with a computer-generated
randomization schedule to receive either 0.5% bupivacaine
or normal saline solution. The central hospital pharmacist
prepared a 1-mL syringe with either the bupivacaine or the
saline solution according to the randomization schedule
and delivered the blinded medication to the research
assistant or treating physician. Both the bupivacaine and
the saline solution were identical in odor, clarity, color, and
consistency. The delivery of the medication to the patient
was thus conducted in a blinded fashion.
Using the Tx360 device, a trained physician administered
0.3 mL of the assigned medication transnasally to the
bilateral posterior nasopharynx in accordance with the device
manufacturer’s instructions (http://tianmedical.com/
Tx360.asp). The device is designed to be positioned in the
anterior nasopharynx, aimed slightly medial and inferior,
with the catheter retracted within the device. Once
positioned, the catheter is advanced from within the device
into the open space of the nasopharynx. The syringe is turned
laterally, which positions the catheter opening at the location
of the sphenopalatine ganglion (Figure 1). The plunger on
the syringe is then pushed to deliver 0.3 mL of the
medication. Bilateral sphenopalatine ganglia are treated
regardless of any laterality of symptoms.
Training for the treating physician required a brief
(<10-minute) tutorial on how to use the device. TrainingVolume 65, no. 5 : May 2015was delivered by another trained physician or a video on the
manufacturer’s Web page. During the course of the study,
17 physicians used the device at least once. None of the
physicians required any retraining, but all had access to the
manufacture’s Web site, pamphlet, and video, and to the
research assistants, who also went through the training.
If after 15 minutes the patients believed that they
required further treatment, the decision was left up to the
discretion of the treating physician. At our institution, the
most common headache therapies currently are intravenous
prochlorperazine and metoclopramide.Methods of Measurement
Pain assessment occurred at 0 (baseline), 5, and 15
minutes. Patients requiring additional treatment for
headache after 15 minutes were offered rescue treatment for
headache or nausea in the ED at the discretion of the
treating physician. We measured pain and nausea through
100-mm, unnumbered, horizontal, visual analog scales.
The research assistant or investigator completed 24-hour
follow-up with the patient through a telephone call
assessing pain and nausea by a 0- to 10-point Likert scale
and assessed any further symptoms, adverse effects, and
return to normal daily activities.
The research assistant collected data on paper forms at
the times speciﬁed. The patients themselves marked the
100-mm visual analog scale to rate their pain and nausea at
the times speciﬁed. At the completion of the ED visit, the
research assistant measured the visual analog scale and
entered the study data into a research electronic data
capture tool hosted at our academic institution for data
management.20 The tool is a secure, Web-based application
designed to support data capture for research studies.Outcomes Measures
The predeﬁned primary endpoint was a 50% absolute
pain reduction on a 100-mm visual analog scale at 15
minutes. We compared the absolute risk difference between
the percentage of subjects in each group achieving this
primary endpoint.
Secondary outcomes included reduction of pain by
greater than 19 mm on the visual analog scale as a
minimally signiﬁcant reduction in pain, nausea reduction,
and percentage of patients who were pain and nausea free at
15 minutes. At 24-hour follow-up, we compared the
medians of the Likert scale responses for both pain and
nausea. We also compared the percentage of patients who
were pain and nausea free at 24 hours. Any adverse events
were recorded, and we assessed nasopharyngeal and other
adverse effects at 24-hour follow-up as well.Annals of Emergency Medicine 505
Figure 2. CONSORT ﬂow diagram for enrollment in the trial.
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A power calculation was completed before the start of
enrollment. The trial was designed to evaluate the
superiority of bupivacaine to normal saline solution as
delivered by the method described. Assuming a 2-sided a
of .05, we calculated that 84 patients were necessary to
achieve 80% power to detect a difference of 30% (30%
meeting the primary endpoint for placebo versus 60% for
bupivacaine) of patients between the 2 groups meeting the
primary endpoint. We performed a c2 test to assess the
difference in the primary endpoint between the 2 groups.
Additionally, we used the Wilcoxon rank sum test to
compare continuous secondary endpoints and demographic
characteristics between the 2 groups. c2 Tests were used to
compare dichotomous secondary endpoints and categorical
demographic characteristics between the 2 groups. Analyses
were performed with SAS (version 9.3) and SigmaPlot
(version 12.5). Graphing of visual analog scale data and
Likert scale dot density plots was performed with






% Female 75.6 71.7
Median age (IQR), y 33 (23–44) 41 (29.25–51)
Median baseline headache score
(IQR), mm
80 (66–93) 78.5 (64–91.75)
Median baseline nausea score (IQR), mm 29 (0–48) 0 (0–45.5)
IQR, Interquartile range.
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Characteristics of Study Subjects
Of 165 patients identiﬁed between October 1, 2012,
and December 10, 2013, we enrolled 93. Four patients
withdrew from the study before receiving the study drug or
placebo through the device. Three of these patients stated
they were anxious about the device or its delivery
mechanism, and the fourth stated after enrollment that he
“might be allergic.” Two patients were excluded after
randomization: one patient was found to be pregnant after
randomization and another patient was enrolled outside of
the age range exclusions. These 6 patients were not
included in the primary analysis; however, we completed a
sensitivity analysis with intention-to-treat principles, and
this is reported as well. Of the remaining patients, 41 were
randomized to receive bupivacaine, and 46 were
randomized to receive saline solution (Figure 2). The 2
groups were similar in terms of sex, baseline headache
score, and baseline nausea score. Although the range of ages
was similar between the 2 groups, the median age of the
bupivacaine group (33 years) was younger than that of the
normal saline solution group (41 years) (Table 1).Main Results
For the primary outcome, there was no difference
between the 2 groups for the percentage of patients
achieving a 50% reduction in headache score at 15 minutes
(Table 2). The risk difference was 7.5% (95% conﬁdence
interval [CI] –13% to 27.1%). Figure 3 shows medians andVolume 65, no. 5 : May 2015
Table 2. Results: headache and nausea at 15 minutes.
Outcome Measure Bupivacaine Saline Solution Difference, % 95% CI
15 min N¼41 N¼46
50% reduction in mm VAS, No. (%) 20 (48.8) 19 (41.3) 7.5 13.0 to 27.1
>19 mm VAS reduction, No. (%) 25 (61.0) 23 (50.0) 11.0 9.6 to 30.3
Headache free (%) 11 (26.8) 12 (26.1) 0.7 17.0 to 19.0
Nausea free (%) 30 (73.0) 32 (69.5) 3.5 15.3 to 21.8
Discharged without rescue medications (%) 18 (43.9) 17 (37.0) 6.9 13.0 to 26.5
Median headache score (IQR), mm VAS 34 (6 to 78) 51.5 (10 to 73.5) 17.5 15.2 to 50.2
Median nausea score (IQR), mm VAS 0 (0 to 4) 0 (0 to 7.25) 0 0.5 to 5
VAS, Visual analog scale.
Schaffer et al Noninvasive Sphenopalatine Ganglion Block for Acute Headacheinterquartile ranges for each group at baseline and at 15
minutes. Also included are the individual patient data pre-
and postintervention, with a line connecting their baseline
and 15-minute visual analog scale scores. We analyzed
the data with an intention-to-treat analysis for the patients
who dropped out before study medication delivery and
for those who were excluded after randomization. This
analysis using a best- or worst-case scenario would not have
changed the signiﬁcance of the results for the primary
endpoint.
Among the secondary outcomes, there was no difference
in patients reporting any ongoing headache at 15 minutes
(risk difference¼0.7%; 95% CI –17.0% to 19.0%). The
percent of patients who were nausea free at 15 minutes was
also similar between the groups (risk difference¼3.5%;
95% CI –15.3% to 21.8%). Patients were discharged
without rescue medication after the 15-minute endpoint in
43.9% of bupivacaine patients and 37.0% of saline
solution patients (risk difference¼6.9%; 95% CI –13.0%
to 26.5%). There was no difference in the median
headache scores on the visual analog scale at 15 minutes.Figure 3. Box plots show median and interquartile ranges for
baseline (pre) and 15-minute (post) headache scores on a 100-
mm visual analog scale. The individual patient response to
therapy for each group is also displayed.
Volume 65, no. 5 : May 2015Next-day follow-up was achieved for 76 patients, 36
(87.8%) randomized to bupivacaine and 40 (87.0%)
randomized to saline solution (Table 3). At 24 hours,
72.2% of the bupivacaine-treated and 47.5% of the saline
solution–treated patients were headache free, representing a
risk difference of 24.7% (95% CI 2.6% to 43.6%). No
nausea was present in 94.4% versus 77.5% of patients,
with a risk difference of 16.9% (95% CI 0.8% to 32.5%).
The median 24-hour headache score (measured on a 10-
point scale) was lower in the bupivacaine group (0 versus 1;
interquartile range 0 to 1.25 versus 0 to 7). Figure 4 shows
the medians and interquartile ranges of headache scores at
24-hour follow-up for all patients for whom follow-up was
achieved, as well as for those who did receive rescue
medications during their index visit.
We performed a post hoc sensitivity analysis, assuming
a worst-case scenario for the secondary endpoint of 24-
hour headache free. In a worst-case scenario (assuming all
patients in both groups lost to follow-up were not
headache free at 24 hours), the overall risk difference was
22.1% (95% CI 1.6% to 42.6%). Of the patients who
did not require any rescue medication and for whom 24-
hour follow-up was achieved, 88.2% (15/17 patients)
versus 56.2% (9/16 patients) were headache free at 24
hours, with a risk difference of 32.0% (95% CI 1.4% to
56.6%).
Patients reported few adverse effects at 24 hours.
Nasopharyngeal symptoms were reported by 5 of 36
patients (13.9%) in the bupivacaine group, and 3 of 40
(7.5%) in the saline solution group reported at the 24-hour
follow-up, an absolute risk difference of 6.4% (95% CI
–8.2% to 22.0%). The symptoms reported were “nasal
dryness,” “runny nose,” “sore throat before going to bed,”
“congestion pre and post,” and “hoarseness” in the
bupivacaine group; and “slight nosebleed,” “slight runny
nose,” and “minor bloody nose in the morning” in the
saline solution group. No severe adverse events were
reported in either group during the ED stay or at 24-hour
follow-up.Annals of Emergency Medicine 507
Table 3. Results: headache and nausea at 24-hour follow-up.
Outcome Measure Bupivacaine Saline Solution Difference, % 95% CI
24 h N¼36 N¼40
Headache free (%) 26 (72.2) 19 (47.5) 24.7 2.6 to 43.6
Nausea free (%) 34 (94.4) 31 (77.5) 16.9 0.8 to 32.5
Median headache score, 0–10 Likert (IQR) 0 (0 to 1.25) 1 (0 to 7) 1 1.4 to 3.4
Median nausea score, 0–10 Likert (IQR) 0 (0 to 0) 0 (0 to 0) 0 0 to 0
24 h: patients without rescue medications N¼17 N¼16
Headache free (%) 15 (88.2) 9 (56.2) 32.0 1.4 to 56.6
Nausea free (%) 17 (100) 14 (87.5) 12.5 8.0 to 36.0
Median headache score, 0–10 Likert (IQR) 0 (0 to 0) 0 (0 to 5.25) 0 2.1 to 2.1
Median nausea score, 0–10 Likert (IQR) 0 (0 to 0) 0 (0 to 0) 0 0 to 0
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There are limitations to this study. We measured
headache severity up until 15 minutes and at 24-hour
follow-up. It is unclear whether sphenopalatine ganglion
block might have shown a beneﬁt at some point after 15
minutes but still during the initial ED encounter. In
retrospect, a 1- or 2-hour assessment would have allowed a
better determination of when the responses to the 2
treatments became divergent. If no difference was apparent
until 24 hours, then sphenopalatine ganglion block would
not be a particularly useful single agent for most ED
headache patients, but headache relief at 1 hour would be
clinically important to patients and emergency
practitioners. When the study protocol was developed, the
timeframe of 15 minutes for efﬁcacy of a sphenopalatine
ganglion block was selected according to previous
studies.12,19 However, bupivacaine as an agent for nerve
block can be slow to absorb and take effect, and this should
have been taken into account. Future studies should assess
initial headache response during a longer initial timeframe.Figure 4. Headache at 24-hour follow-up. Box plots show
median and interquartile ranges for Likert score (0 to 10) for all
patients for whom follow-up was obtained and for the group
that did not receive rescue medicines after the intervention.
508 Annals of Emergency MedicineThe median age of the bupivacaine group was 8 years
younger than that of the saline solution–treated group. The
age difference did not reach statistical signiﬁcance and the
age ranges in the 2 groups are similar. We are unaware of
any clinical or pathophysiologic evidence to suggest that
there would be a difference in headache response according
to age. We completed a logistic regression analysis to adjust
for the difference in age between groups, which did not
signiﬁcantly change the results for the primary endpoint.
There was the potential for unblinding. Although the
medications were identical in many ways, bupivacaine and
saline solution are different in taste and the production of
anesthesia. The small volume of medication, as well as the
localized spray, should limit the amount of medication
available to the oropharynx, but there is the potential for
anesthetic to create an identiﬁable taste and unblind the
patient. Both bupivacaine and saline solution have a
noxious taste and most patients have had no experience
with which to compare the two. It is unclear what effect the
potential for unblinding of patients would have had in our
study. Given the relatively impressive therapeutic response
in the saline solution–treated patients, it seems unlikely
that unblinding, if it occurred, produced any signiﬁcant
effect.
Approximately 13% of our patients were lost to 24-hour
follow-up. The number of patients lost to follow-up was
similar in the 2 arms of the study. A post hoc sensitivity
analysis found that this would not have signiﬁcantly altered
the 24-hour secondary outcomes.
We found that both bupivacaine and saline solution
sphenopalatine ganglion block produced complete
headache resolution in 26% of patients at 15 minutes, and
that either treatment produced a 50% reduction in
headache at 15 minutes in greater than 40% of patients.
Although a substantial placebo effect is common in studies
of headache therapy, these results are impressive for a true
placebo.21,22 It is possible that the sphenopalatine ganglion
was stimulated mechanically because of the pressure of the
spray or even by the absorption of saline solution itself,Volume 65, no. 5 : May 2015
Schaffer et al Noninvasive Sphenopalatine Ganglion Block for Acute Headacheproducing a therapeutic effect. Using a sham device that
sprays to a different location than the sphenopalatine
ganglion may be a better control for assessing a difference
between groups.
The ﬁndings of beneﬁts at 24 hours were secondary
outcomes and need to be validated in further studies.
Although the 24-hour results showed consistent beneﬁt
with bupivacaine sphenopalatine ganglion block, we
assessed multiple secondary endpoints, increasing the
possibility of ﬁnding differences caused by chance alone.
Last, this was a relatively small study conducted at 2
academic EDs associated with a single teaching institution.
Future work will be needed to determine whether these
results are reproducible in other clinical environments.
DISCUSSION
We completed a double-blind, randomized trial of
sphenopalatine ganglion block in the ED, using
bupivacaine delivered by the Tx360 device. In this study,
bupivacaine was not shown to have an immediate beneﬁt
over normal saline solution placebo for the primary
outcome of a greater than or equal to 50% reduction in
headache severity at 15 minutes. The bupivacaine group
also did not show beneﬁts in the secondary outcomes
assessed at the 15-minute interval.
The ﬁnding of no immediate beneﬁt is surprising, given
the proposed mechanism of action of sphenopalatine
ganglion block, as well as the results from Maizels and
Geiger.12 These authors demonstrated an immediate
beneﬁt of sphenopalatine ganglion block for migraine
treatment with conventional transnasal approach of
topically dripped lidocaine versus saline solution in a
recumbent patient. There are several possible explanations
about why this might have occurred in our study. One
explanation is that sphenopalatine ganglion block with
bupivacaine may take longer than 15 minutes to have the
desired effect in some patients. For the primary outcome,
we did not assess the timeframe beyond the initial 15
minutes after study drug delivery, the reasoning being that
rescue medications would confound any outcomes after
that. The majority of patients in both groups received
rescue medication after the 15-minute efﬁcacy assessment.
This study may have beneﬁted from a longer primary
outcome assessment.
Another explanation may be the size of the placebo
effect in this study. More than 40% in each group had a
signiﬁcant reduction in headache at the primary endpoint
of 15 minutes. Placebo effect has been well documented in
headache trials; however, these are still striking results to be
achieved with a true placebo in only 15 minutes.21,22 HalfVolume 65, no. 5 : May 2015of the patients in the placebo group versus 61% in the
bupivacaine group had a 20-mm or greater reduction in
headache at 15 minutes. More than 26% of patients in
both the bupivacaine group and the saline solution group
reported complete resolution of headache at 15 minutes.
And maybe most important to emergency physicians,
43.9% of the bupivacaine group and 37% of the placebo
group were able to be discharged from the ED after the 15-
minute time from drug delivery, without further treatment.
Given the design of our study, it is possible that
stimulation of the sphenopalatine ganglion in the placebo
group produced a short-lived reduction in headache
symptoms, whereas bupivacaine acts to produce a more
lasting effect because of its anesthetic properties. It is
believed that other forms of stimulation of the
sphenopalatine ganglion, such as electrical, can abort
headache.11,23 Thus, it is possible that mechanical
stimulation of the sphenopalatine ganglion by the spray of
saline solution or chemical changes in the ganglion from
the absorption of saline solution itself resulted in some
beneﬁt. To test these hypotheses, a better sham could be
designed.
Despite the ﬁnding of no immediate difference between
bupivacaine and placebo, at 24 hours more patients in the
bupivacaine group were headache free and nausea free than
in the placebo group. This ﬁnding may lend support to
some of the theories above, but conﬁrming or refuting
beneﬁt at 24 hours will require further study. This study
was not designed or powered to speciﬁcally examine this
outcome, so it is possible that we simply experienced a type
I error. There is also the possibility that sphenopalatine
ganglion block has some effect when used independently
but works synergistically with dopamine antagonists, our
typical rescue agents, to have a stronger effect. Although
there was no difference in the outcomes measured before
rescue medication at 15 minutes, there were apparent
differences by 24 hours, after rescue medications had been
offered. It is unclear when the apparent efﬁcacy in the 2
treatment arms became divergent. Although synergy is a
possibility, it seems unlikely to completely explain the
results, given the ﬁnding that the 24-hour beneﬁt appeared
to be sustained in patients who did not receive rescue
medications. Given these ﬁndings, the possibility remains
that sphenopalatine ganglion block with this device has a
role in the treatment of acute anterior headache in the ED.
There are some important questions raised by these data
for future study. One is whether mechanical stimulation of
the sphenopalatine ganglion plays a role in the early relief
of headache. A related question is the suggestion by the
24-hour outcomes that there is a prolonged effect ofAnnals of Emergency Medicine 509
Noninvasive Sphenopalatine Ganglion Block for Acute Headache Schaffer et albupivacaine versus saline solution. A third question is the
synergistic role of sphenopalatine ganglion block along with
conventional therapy. In retrospect, a better sham might
have been designed to act as control for sphenopalatine
ganglion block in this study and would be important to
develop for future trials.
In conclusion, sphenopalatine ganglion block with the
Tx360 device with bupivacaine did not result in a
signiﬁcant increase in the proportion of patients achieving
the primary outcome of a greater than or equal to 50%
reduction in headache severity at 15 minutes compared
with saline solution applied in the same manner. However,
several questions were raised in this study and warrant
further trials to evaluate the role of sphenopalatine block in
acute headache care in the ED.
Supervising editor: Donald M. Yealy, MD
Author afﬁliations: From the Department of Emergency Medicine
(Schaffer, Hunter, Weaver), Indiana University School of Medicine
(Ball), Indianapolis, IN.
Author contributions: JTS and CSW conceived the study and
designed the trial. JTS, BRH, and KMB supervised the data
collection. All authors drafted the article and contributed
substantially to its revision. JTS takes responsibility for the paper
as a whole.
Funding and support: By Annals policy, all authors are required to
disclose any and all commercial, ﬁnancial, and other relationships
in any way related to the subject of this article as per ICMJE conﬂict
of interest guidelines (see www.icmje.org). Research funding for
this trial was provided by Tian Medical LLC, makers of the Tx360
device (Indiana University award 045545-00001A). The grant was
awarded to the Indiana University Department of Emergency
Medicine (IUDEM) and supported a portion of the time for Dr.
Schaffer through IUDEM to complete this study. Dr. Ball was paid
an hourly rate through IUDEM from these funds for his time
enrolling patients. None of the authors collected any direct moneys
or other payments from the sponsor.
Publication dates: Received for publication July 30, 2014.
Revision received October 23, 2014. Accepted for publication
December 3, 2014. Available online January 7, 2015.
Presented at the Society for Academic Emergency Medicine annual
meeting, May 2014, Dallas, TX.
The sponsor had had no role in the design and conduct of the
study; collection, management, and analysis of the data; or
preparation, review, and approval of the article.
REFERENCES
1. Nawar EW, Niska RW, Xu J. National Hospital Ambulatory Medical Care
Survey: 2005 emergency department summary. Adv Data.
2007;386:1-32.
2. Goldstein JN, Camargo CA, Pelletier AJ, et al. Headache in United
States emergency departments: demographics, work-up and510 Annals of Emergency Medicinefrequency of pathological diagnoses. Cephalalgia. 2006;26:
684-690.
3. Morgenstern LB, Huber JC, Luna-Gonzales H, et al. Headache in the
emergency department. Headache. 2001;41:537-541.
4. Richman PB, Reischel U, Ostrow A, et al. Droperidol for acute migraine
headache. Am J Emerg Med. 1999;17:398-400.
5. Jones J, Sklar D, Dougherty J, et al. Randomized double-blind trial of
intravenous prochlorperazine for the treatment of acute headache.
JAMA. 1989;261:1174-1176.
6. Weaver CS, Jones JB, Chisholm CD, et al. Droperidol vs. prochlorperazine
for the treatment of acute headache. J Emerg Med. 2004;26:145-150.
7. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled
evaluation of prochlorperazine versus metoclopramide for emergency
department treatment of migraine headache. Ann Emerg Med.
1995;26:541-546.
8. Yarnitsky D, Goor-Aryeh I, Bajwa ZH, et al. 2003 Wolff Award: possible
parasympathetic contributions to peripheral and central sensitization
during migraine. Headache. 2003;43:704-714.
9. Maizels M. Intranasal lidocaine to prevent headache following
migraine aura. Headache. 1999;39:439-442.
10. Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding
and treatment. N Engl J Med. 2002;346:257-270.
11. Tepper SJ, Rezai A, Narouze S, et al. Acute treatment of intractable
migraine with sphenopalatine ganglion electrical stimulation.
Headache. 2009;49:983-989.
12. Maizels M, Geiger AM. Intranasal lidocaine for migraine: a randomized
trial and open-label follow-up. Headache. 1999;39:543-551.
13. Piagkou M, Demesticha T, Troupis T, et al. The pterygopalatine
ganglion and its role in various pain syndromes: from anatomy to
clinical practice. Pain Pract. 2012;12:399-412.
14. DeMaria S, Govindaraj S, Chinosorvatana N, et al. Bilateral
sphenopalatine ganglion blockade improves postoperative analgesia
after endoscopic sinus surgery. Am J Rhinol Allergy. 2012;26:e23-e27.
15. Cho D-Y, Drover DR, Nekhendzy V, et al. The effectiveness of
preemptive sphenopalatine ganglion block on postoperative pain and
functional outcomes after functional endoscopic sinus surgery. Int
Forum Allergy Rhinol. 2011;1:212-218.
16. Manahan AP, Malesker MA, Malone PM. Sphenopalatine ganglion
block relieves symptoms of trigeminal neuralgia: a case report. Nebr
Med J. 1996;81:306-309.
17. Nguyen M, Wilkes D. Pulsed radiofrequency V2 treatment and
intranasal sphenopalatine ganglion block: a combination therapy for
atypical trigeminal neuralgia. Pain Pract. 2010;10:370-374.
18. Murty PS, Prasanna A. Endoscopic sphenopalatine ganglion block
for pain relief. Indian J Otolaryngol Head Neck Surg. 1998;50:
99-105.
19. Candido KD, Massey ST, Sauer R, et al. A novel revision to the
classical transnasal topical sphenopalatine ganglion block for the
treatment of headache and facial pain. Pain Physician.
2013;16:E769-E778.
20. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture
(REDCap)—a metadata-driven methodology and workﬂow process for
providing translational research informatics support. J Biomed Inform.
2009;42:377-381.
21. De Groot FM, Voogt-Bode A, Passchier J, et al. Headache: the placebo
effects in the control groups in randomized clinical trials; an analysis
of systematic reviews. J Manipulative Physiol Ther. 2011;34:
297-305.
22. Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered placebo and
drug labeling changes the outcome of episodic migraine attacks. Sci
Transl Med. 2014;6:218ra5.
23. Ansarinia M, Rezai A, Tepper SJ, et al. Electrical stimulation of
sphenopalatine ganglion for acute treatment of cluster headaches.
Headache. 2010;50:1164-1174.Volume 65, no. 5 : May 2015
